Vir Biotechnology Stock News

Bank of America Corp DE lifted its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 30.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 233,674 shares of the companys stock after buying an additional 54,888 shares during the quarter. Bank of []

Man Group plc lifted its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 9.5% during the second quarter, Holdings Channel.com reports. The fund owned 8,008 shares of the companys stock after purchasing an additional 695 shares during the period. Man Group plcs holdings in Vir Biotechnology were worth $378,000 at the end of the []

Vir Biotechnology Inc. (NASDAQ:VIR) price on Friday, November 19, rose 3.34% above its previous days close as an upside momentum from buyers pushed the stocks value to $32.75. A look at the stocks price movement, the close in the last trading session was $31.69, moving within a range at $31.75 and $33.19. Turning to its Vir Biotechnology Inc. (NASDAQ: VIR): The Metrics That Matter Right Now Read More »

Needham & Company LLC restated their buy rating on shares of Vir Biotechnology (NASDAQ:VIR) in a report published on Wednesday morning, Price Targets.com reports. They currently have a $79.00 target price on the stock. A number of other research analysts have also weighed in on the company. TheStreet lowered Vir Biotechnology from a c- rating []

Vir Biotechnology, Inc. (NASDAQ:VIR) insider Phillip Pang sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 17th. The stock was sold at an average price of $35.85, for a total value of $179,250.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is […]

GlaxoSmithKline (GSK) and Vir Biotechnology have secured contracts from the US government for nearly $1bn to supply their Covid-19 antibody treatment, sotrovimab. Sotrovimab is an investigational single-dose SARS-CoV-2 The post GSK and Vir to supply Covid-19 antibody treatment doses to US appeared first on Pharmaceutical Business review .

Glaxo (GSK) and Vir Biotechnology (VIR) sign purchase contract with the U.S. government to supply doses of sotrovimab worth approximately $1 billion by next month.

Needham & Company LLC reissued their buy rating on shares of Vir Biotechnology (NASDAQ:VIR) in a research report sent to investors on Wednesday, PriceTargets.com reports. They currently have a $79.00 target price on the stock. Several other research firms also recently issued reports on VIR. Barclays decreased their price objective on shares of Vir Biotechnology []

Britains GlaxoSmithKline plc (LON: GSK) announced in a joint statement with the U.S. based Vir Biotechnology Inc (NASDAQ: VIR) on Wednesday that the U.S. government had agreed to buy about $1.0 billion worth of its antibody-based COVID-19 treatment. U.S. wants GSK to deliver the doses by December 17th The number of doses of Sotrovimab [] The post U.S. places a sizable order for GSK-Virs COVID-19 treatment appeared first on Invezz .

George Scangos, Vir Biotechnology president & CEO, joins 'Power Lunch' in an interview with CNBC's Meg Tirrell after Vir secured a $1 billion deal with the U.S. government with it's Covid antibody dru

The United States government has signed contracts worth about $1 billion to secure the antibody-based COVID-19 treatment developed by GlaxoSmithKline plc (NYSE: GSK ) and Vir Biotechnology Inc (NASDAQ: VIR ). GSK said the deal brought the total number of doses secured for the treatment, sotrovimab, to more than 750,000 globally. The U.S. deliveries of sotrovimab are expected by … Full story available on Benzinga.com

Britain's GlaxoSmithKline plc (LON: GSK) announced in a joint statement with the U.S. based Vir Biotechnology Inc (NASDAQ: VIR) on Wednesday that the U.S. government had agreed to buy about $1.0 billi

A COVID-19 BREAKTHROUGH has been made as UK drugmaker GlaxoSmithKline has signed a huge $1billion deal with US-based Vir Biotechnology.

WASHINGTON, Nov 17 The United States has signed contracts worth roughly US$1 billion (RM4.18 billion) to secure the antibody-based Covid-19 treatment sotrovimab from GSK and Vir Biotechnology, the drugmakers said on Wednesday, with supply